cancer immunology immunotherapy

期刊名称 cancer immunology immunotherapy 

期刊缩写 CANCER IMMUNOL IMMUN   
学科分类 医学 

出版周期 月刊   
审稿速度 1 个月 （平均） 

投稿命中率 不详   
期刊主页 http://www.springer.com/medicine/oncology/journal/262   
ISSN 号 (printed): 0340-7004 (electronic): 1432-0851   
IF 趋势    2005     2006     2007      2008     2009     2010     2011     2012   
              4.086    4.313     3.728     3.804    3.791     4.293    3.701    3.637   
被收录情况   1. Science Citation Index 
                    2. Science Citation Index Expanded 
                    3. Current Contents - Life Sciences 
                    4. BIOSIS Previews   
PubSci评语 审稿周期快，发表周期也快。无版面费，IF较为坚挺。编辑很友好，回复很及时，强烈建议尝试。   
期刊简介 自1976年创刊以来，CII展示了肿瘤免疫学领域的显著进步，为基础、转化医学、临床癌症免疫学以及免疫治疗领域的新概念和进展提供了一个交流的平台。CII热衷于发表综述和有深远意义的想法，比如延长或挑战现有既定模式的结果、不支持目前模式的阴性实验结果、在不同领域上重复别人成功结果的研究等。   
投稿注意事项 特别提醒：彩页免费。常规论文方式不收费，Open Access方式收取3000美元或2200欧元。无版面费。
一般注意事项：
Types of Papers
The journal Cancer Immunology, Immunotherapy publishes the following types of papers:
Original Article – word limit ca. 4000 words, ca. 45 references, no more than six figures/tables excluding supplementary on-line only material.
Letter to the Editors – CII occasionally accepts letters to the Editors pertaining to articles published in the Journal. Text is limited to 750 words, with no abstract and no keywords, but including a précis. There may be one figure, up to three references, and no more than three authors, with author affiliations only including main institution, place name and (state plus) country (i.e. no departments, etc.). As for any other manuscript, the full details of the corresponding author and a conflict of interest statement must be included.
Opinion Paper – presents a novel or innovative interpretation of published data.
Commentary - discusses a paper(s) published in Cancer Immunology, Immunotherapy or elsewhere in which the authors of the Commentary provide additional data and insight that either support or refute the original publication.
Review – generally by invitation only, but unsolicited proposals accompanied by an abstract and outline can be sent to the Editors-in-Chief for consideration prior to submission.
Focussed Research Review – by invitation only. FRRs are based on presentations made at conferences, primarily intended to review the author´s own work in a particular area. They should provide the background for the "personal" review and not be a general overview of the field, and may present opinions or hypotheses. They may include original data, but previously published material must have copyright clearance. Articles should be 2,000-5,000 words, with a maximum of 50 references and 2-3 explanatory display items, preferably figures. They should include an abstract, but the remainder of the paper can be structured as desired as long as the general CII "Instructions for Authors" are adhered to. Manuscripts must be submitted as a Focussed Research Review (not as a Review) to the Editor-in-Chief who invited the submission. Specify the invitation (conference title, location and date) in the comments for the Editorial Office. FRRs are subject to the usual peer review process, and invitation to submit does not guarantee acceptance. Articles will be published on-line in the order of acceptance, but the print version will bring together all papers from a particular conference, together with a meeting report, if available.
Symposium-in-Writing Paper – by invitation only. SIW consist of a minimum of 3 articles, each written by different authors, focussed on a particular theme. They are from “virtual” symposia, not originating from a real-world conference and follow the guidelines for Focussed Research Reviews (see above). Individual SIW papers are submitted to the Editor-in-Chief who invited the SIW, and must indicate the title of the Symposium-in-Writing in comments for the Editorial Office. Investigators who would like to organize a “Symposium-in-Writing” on a special topic should contact the appropriate Editor-in-Chief.
Editorial – by invitation only.
Meeting Report – contact the Editor-in-Chief before submitting. Conference organizers should approach the appropriate EiC in advance of their meeting. CII is interested in the rapid publication of conference summaries. These should tell a scientific “story” and not be simply a list of speakers´ statements and must focus exclusively on the scientific activities of the conference. There is no formal limit to the length of meeting summaries but reports should be concise. The manuscript title must include the exact name of the conference and its acronym, the exact dates and the conference location (city and country). The title should not contain the words “meeting report” or anything like “report from”. Such manuscripts must be submitted without abstract, references, figures, tables, or photos. Meeting Reports must include a précis (see below) and conflict of interest statements for all authors. Cited speakers must be identified in bold type, followed by their institutions and locations in brackets. All cited speakers must approve the manuscript prior to submission and the submitting authors must confirm this approval in the comments for the Editorial Office. Meeting reports will be peer-reviewed by two meeting attendees and by two reviewers who did not attend the meeting. These reviewers must be suggested by the authors.
Manuscript submission
Manuscript Submission
Submission of a manuscript implies: that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities – tacitly or explicitly – at the institute where the work has been carried out. The publisher will not be held legally responsible should there be any claims for compensation.
Permissions
Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.
Online Submission
Authors should submit their manuscripts online. Electronic submission substantially reduces the editorial processing and reviewing times and shortens overall publication times. Please follow the hyperlink “Submit online” on the right and upload all of your manuscript files following the instructions given on the screen.
Authorship, Criteria and Contributions
All authors must approve all versions of a submitted manuscript. All authors of accepted articles must accept responsibility for the manuscript’s content by signing an authorship form affirming that they have met the following three criteria for authorship:
1. Substantial contributions to conception and design, acquisition of data, and/or analysis and interpretation of results.
2. Substantial scientific and intellectual contributions to the drafting or rewriting of the initial and/or revised manuscript.
3. Approval of the final accepted version of the manuscript.
It is not sufficient merely to have provided funding or materials.
Redundant, Duplicate or Faudulent Publication
Manuscripts submitted to Cancer Immunology, Immunotherapy must not be simultaneously submitted to another publication.
Manuscripts must contain original work that has not previously been published in other print or digital form except as an abstract at a conference. Such abstracts must be acknowledged in the submitted paper.
Manuscripts must not contain materials published in other print or electronic media without written permission from the relevant publisher. The publisher of Cancer Immunology, Immunotherapy will not be held legally responsible should there be any claims for compensation.
Manuscripts must not contain falsified data.
Manuscripts must not contain original data generated by non-authors.
Manuscripts must cite the work of other investigators which established priority.
Authors wishing to include figures, tables, or text passages that have been published elsewhere must obtain and submit written permission from the copyright owner(s) for both the print and on-line format at the time of initial manuscript submission. Any material received without such evidence will be assumed to originate from the authors.
Please note:
At the end of the submission process, carefully check the automatically-created PDF. It is the responsibility of the submitting author to ensure that this PDF contains the correct and complete text, graphic materials, symbols, mathematical signs, etc. Conversion problems can occur and if not corrected, may affect the evaluation of a manuscript.
Editorial Procedure
Selection of Editor-in-Chief (for Manuscript Submission)
Dr. Suzanne Ostrand-Rosenberg is the Editor-in-Chief for manuscripts in which the reported studies were performed in the Americas, China or Japan.
Dr. Graham Pawelec is the Editor-in-Chief for manuscripts in which the reported studies were performed in all other countries.
Invited manuscripts are to be submitted to the Editor-in-Chief who issued the invitation and must specify the invitation in the comments for the Editorial Office.
Review Procedures
Manuscripts are initially evaluated by the managing Editor-in-Chief according to the following criteria:
• Relevance to the aims of the Journal and the field of cancer immunology and immunotherapy.
• Subject matter that is of general interest to the readership of the Journal and will contribute to the advancement of the field.
• Originality.
• Appropriate study design and methodology.
• Conclusions which are supported by the data.
• Focused and concise writing style.
Manuscripts that do not meet these criteria will be returned to the author without review.
Manuscripts that meet these criteria will be further evaluated by a minimum of two expert reviewers who will anonymously provide unbiased, critical and independent assessment of the submission. The Editor-in-Chief will make a final decision on the disposition of the manuscript based on the recommendations of these reviewers. Authors are encouraged to provide the full names and contact information of potential reviewers who have expertise in the subject of the manuscript. Authors may request the exclusion of specific reviewers and should provide justification for the request. The corresponding author will be notified of the editorial decision by E-mail which may include some or all of the reviewers' comments.
Revised Manuscripts
Manuscripts which are returned to the authors for minor or major modifications must be resubmitted within 6 months. Manuscripts not submitted within this timeframe will be withdrawn. If additional time is needed, the Editor-in-Chief must be contacted well before the manuscript is automatically withdrawn. A letter must accompany the revised manuscripts reiterating the reviewers' and Editor's comments and providing a point-by-point response to each of these comments. Revisions to the manuscript must be identified by highlighting with a gray or yellow background. "Tracking" mode in Word is not acceptable. Changes in the PDF of supplementary materials should not be highlighted, but must be explained in the point-by-point response. Only the highlighted version of the revised manuscript should be submitted; do not submit an additional “clean” version. Revised manuscripts will be re-evaluated by the external reviewers who will assess new data and determine if the authors have satisfactorily responded to the initial critiques. Depending on this evaluation, the manuscript may be accepted or rejected at the discretion of the Editor-in-Chief. Questions or concerns regarding an editorial decision must be submitted within one month of completion of the review.
Confidentiality
All manuscripts are treated as privileged and confidential information. Reviewers may request advice from another party, subject to the general principles of confidentiality and permission of the Editor-in-Chief. Invited reviewers unable to accept an invitation to assess a paper are encouraged to suggest alternative reviewers; however, an invited reviewer must not pass any manuscript to another person without prior approval of the Editor-in-Chief. Reviewers’ comments are not published or made available publicly except with the prior written permission of the reviewer, author, and Editor-in-Chief. However, all reviewer comments for the authors are visible to all other reviewers of the same manuscript. The reviewers’ identities remain undisclosed. Reviewers must consider potential conflicts of interest that could influence their recommendations and if necessary discuss these with the Editor-in-Chief prior to undertaking the review.
Title page
Title Page
The title page should include:
The name(s) of the author(s)
A concise and informative title
The affiliation(s) and address(es) of the author(s)
The e-mail address, telephone and fax numbers of the corresponding author
Abstract
Please provide an abstract of 150 to 250 words. The abstract should not contain any undefined abbreviations or unspecified references.
Keywords
Please provide 4 to 6 keywords which can be used for indexing purposes.
Précis
Provide one or two succinct sentences (not just keywords) highlighting what makes the manuscript especially interesting and significant. The précis will be included in the table of contents alerts and must not exceed 250 characters, including spaces. It must not be written in the first person (I, we, my, our), must not include the word “manuscript” and should not repeat the title.
Introduction, Materials and Methods, Results and Discussion
The Introduction must provide sufficient background to understand the significance of the content but should not include a general review of the field.
Materials and Methods must contain sufficient information so that experimental procedures can be reproduced. Materials and Methods or parts thereof must not be transferred into the supplementary, on-line only materials. If animals and/or human subjects were used, a statement documenting the approval of their use must be included. The Editors encourage but do not require that papers describing T cell assays with human cells comply with the MIATA recommendations for reporting such methods. These recommendations may be seen at http://miataproject.org/. If applied, the authors should provide a statement that their paper is MIATA-compliant and should include the MIATA checklist in the “Supplementary” files. Accepted papers following MIATA guidelines will be prominently labeled as such in their published version, and contain the statement “The authors of this paper report on their T cell assays transparently and comprehensively as per field-wide consensus, allowing the community a full understanding and interpretation of presented data as well as a comparison of data between groups.”
The Discussion follows the Results section and must interpret the experimental findings in the context of the state-of-the-art and not simply reiterate data in the Results.

Text
Text Formatting
Manuscripts should be submitted in Word.
Use a normal, plain font (e.g., 10-point Times Roman) for text.
Use italics for emphasis.
Use the automatic page numbering function to number the pages.
Do not use field functions.
Use tab stops or other commands for indents, not the space bar.
Use the table function, not spreadsheets, to make tables.
Use the equation editor or MathType for equations.
Save your file in docx format (Word 2007 or higher) or doc format (older Word versions).
Manuscripts with mathematical content can also be submitted in LaTeX.
LaTeX macro package (zip, 182 kB)
Headings
Please use no more than three levels of displayed headings.
Abbreviations
Abbreviations should be defined at first mention and used consistently thereafter.
Footnotes
Footnotes can be used to give additional information, which may include the citation of a reference included in the reference list. They should not consist solely of a reference citation, and they should never include the bibliographic details of a reference. They should also not contain any figures or tables.
Footnotes to the text are numbered consecutively; those to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data). Footnotes to the title or the authors of the article are not given reference symbols.
Always use footnotes instead of endnotes.
Acknowledgments
Acknowledgments of people, grants, funds, etc. should be placed in a separate section before the reference list. The names of funding organizations should be written in full.
Specific Remark on Abbreviations
Non-standard abbreviations should be defined on the cover page and at first mention in the text and used consistently thereafter.
Scientific style
Please always use internationally accepted signs and symbols for units (SI units).
Nomenclature: Insofar as possible, authors should use systematic names similar to those used by Chemical Abstract Service or IUPAC.
Genus and species names should be in italics.
Generic names of drugs and pesticides are preferred; if trade names are used, the generic name should be given at first mention.
References
Citation
Reference citations in the text should be identified by numbers in square brackets. Some examples:
1. Negotiation research spans many disciplines [3].
2. This result was later contradicted by Becker and Seligman [5].
3. This effect has been widely studied [1-3, 7].
Reference list
The list of references should only include works that are cited in the text and that have been published or accepted for publication. Personal communications and unpublished works should only be mentioned in the text. Do not use footnotes or endnotes as a substitute for a reference list.
The entries in the list should be numbered consecutively.
Journal article
Gamelin FX, Baquet G, Berthoin S, Thevenet D, Nourry C, Nottin S, Bosquet L (2009) Effect of high intensity intermittent training on heart rate variability in prepubescent children. Eur J Appl Physiol 105:731-738. doi: 10.1007/s00421-008-0955-8
Ideally, the names of all authors should be provided, but the usage of “et al” in long author lists will also be accepted:
Smith J, Jones M Jr, Houghton L et al (1999) Future of health insurance. N Engl J Med 965:325–329
Article by DOI
Slifka MK, Whitton JL (2000) Clinical implications of dysregulated cytokine production. J Mol Med. doi:10.1007/s001090000086
Book
South J, Blass B (2001) The future of modern genomics. Blackwell, London
Book chapter
Brown B, Aaron M (2001) The politics of nature. In: Smith J (ed) The rise of modern genomics, 3rd edn. Wiley, New York, pp 230-257
Online document
Cartwright J (2007) Big stars have weather too. IOP Publishing PhysicsWeb. http://physicsweb.org/articles/news/11/6/16/1. Accessed 26 June 2007
Dissertation
Trent JW (1975) Experimental acute renal failure. Dissertation, University of California
Always use the standard abbreviation of a journal’s name according to the ISSN List of Title Word Abbreviations, see
www.issn.org/2-22661-LTWA-online.php
For authors using EndNote, Springer provides an output style that supports the formatting of in-text citations and reference list.
EndNote style (zip, 2 kB)
Authors preparing their manuscript in LaTeX can use the bibtex file spbasic.bst which is included in Springer’s LaTeX macro package.
Tables
All tables are to be numbered using Arabic numerals.
Tables should always be cited in text in consecutive numerical order.
For each table, please supply a table caption (title) explaining the components of the table.
Identify any previously published material by giving the original source in the form of a reference at the end of the table caption.
Footnotes to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data) and included beneath the table body.
Artwork and Illustrations Guidelines
For the best quality final product, it is highly recommended that you submit all of your artwork – photographs, line drawings, etc. – in an electronic format. Your art will then be produced to the highest standards with the greatest accuracy to detail. The published work will directly reflect the quality of the artwork provided.
Electronic Figure Submission
Supply all figures electronically.
Indicate what graphics program was used to create the artwork.
For vector graphics, the preferred format is EPS; for halftones, please use TIFF format. MS Office files are also acceptable.
Vector graphics containing fonts must have the fonts embedded in the files.
Name your figure files with "Fig" and the figure number, e.g., Fig1.eps.
Line Art
 
Definition: Black and white graphic with no shading.
Do not use faint lines and/or lettering and check that all lines and lettering within the figures are legible at final size.
All lines should be at least 0.1 mm (0.3 pt) wide.
Scanned line drawings and line drawings in bitmap format should have a minimum resolution of 1200 dpi.
Vector graphics containing fonts must have the fonts embedded in the files.
Halftone Art
 
Definition: Photographs, drawings, or paintings with fine shading, etc.
If any magnification is used in the photographs, indicate this by using scale bars within the figures themselves.
Halftones should have a minimum resolution of 300 dpi.
Combination Art
 
Definition: a combination of halftone and line art, e.g., halftones containing line drawing, extensive lettering, color diagrams, etc.
Combination artwork should have a minimum resolution of 600 dpi.
Color Art
Color art is free of charge for online publication.
If black and white will be shown in the print version, make sure that the main information will still be visible. Many colors are not distinguishable from one another when converted to black and white. A simple way to check this is to make a xerographic copy to see if the necessary distinctions between the different colors are still apparent.
If the figures will be printed in black and white, do not refer to color in the captions.
Color illustrations should be submitted as RGB (8 bits per channel).
Figure Lettering
To add lettering, it is best to use Helvetica or Arial (sans serif fonts).
Keep lettering consistently sized throughout your final-sized artwork, usually about 2–3 mm (8–12 pt).
Variance of type size within an illustration should be minimal, e.g., do not use 8-pt type on an axis and 20-pt type for the axis label.
Avoid effects such as shading, outline letters, etc.
Do not include titles or captions within your illustrations.
Figure Numbering
All figures are to be numbered using Arabic numerals.
Figures should always be cited in text in consecutive numerical order.
Figure parts should be denoted by lowercase letters (a, b, c, etc.).
If an appendix appears in your article and it contains one or more figures, continue the consecutive numbering of the main text. Do not number the appendix figures, "A1, A2, A3, etc." Figures in online appendices (Electronic Supplementary Material) should, however, be numbered separately.
Figure Captions
Each figure should have a concise caption describing accurately what the figure depicts. Include the captions in the text file of the manuscript, not in the figure file.
Figure captions begin with the term Fig. in bold type, followed by the figure number, also in bold type.
No punctuation is to be included after the number, nor is any punctuation to be placed at the end of the caption.
Identify all elements found in the figure in the figure caption; and use boxes, circles, etc., as coordinate points in graphs.
Identify previously published material by giving the original source in the form of a reference citation at the end of the figure caption.
Figure Placement and Size
When preparing your figures, size figures to fit in the column width.
For most journals the figures should be 39 mm, 84 mm, 129 mm, or 174 mm wide and not higher than 234 mm.
For books and book-sized journals, the figures should be 80 mm or 122 mm wide and not higher than 198 mm.
Permissions
If you include figures that have already been published elsewhere, you must obtain permission from the copyright owner(s) for both the print and online format. Please be aware that some publishers do not grant electronic rights for free and that Springer will not be able to refund any costs that may have occurred to receive these permissions. In such cases, material from other sources should be used.
Accessibility
In order to give people of all abilities and disabilities access to the content of your figures, please make sure that
All figures have descriptive captions (blind users could then use a text-to-speech software or a text-to-Braille hardware)
Patterns are used instead of or in addition to colors for conveying information (color-blind users would then be able to distinguish the visual elements)
Any figure lettering has a contrast ratio of at least 4.5:1
Cover Art
Cancer Immunology, Immunotherapy welcomes suggestions of material as potential cover art. After a manuscript is accepted for publication, the corresponding author may contact the Editor-in-Chief or the Editorial Office with suitable material that illustrates the significance/impact of the paper. This material should be in color and can be a figure from the manuscript, a modification of a figure from the manuscript, a schematic illustration of the study, or any combination of these and/or other relevant materials. The material must be formatted according to the guidelines for graphic art (see below) and be sized to fit within an 18.41 cm (width) by 12.28 cm (height) space.
Electronic Supplementary Material
(On-line Only Materials)
Cancer Immunology, Immunotherapy accepts figures, tables, the above mentioned MIATA checklist and small videos as supplementary, on-line materials.
All Materials and Methods must be included in the manuscript text; they must not be in the on-line only materials.
Electronic supplementary materials will be published as submitted without conversion, editing, or reformatting.
Each supplementary item (figure, table, video, etc.) must be numbered and cited in the text in the numerical order in which it appears, and must be called “supplementary figure”, "supplementary table", "supplementary media”, "supplementary video", "supplementary audio", “supplementary animation", or "supplementary MIATA information."
The MPEG-1 (.mpg) format is used for audio, video, and animations. Large-sized files may require very long download times and be problematic to upload.
Other on-line only materials must be submitted as PDFs. Supplementary tables and figures must be included in a single PDF starting with “supplementary Table 1” (followed by all other supplementary tables) or "supplementary Figure 1" (followed by all other supplementary figures). A title and caption for figures or a legend for tables must appear immediately below each figure or table. Supplementary figure captions and supplementary table legends must not be included in the manuscript text.
Supplementary materials must contain only the supplementary figure, table, video etc. and relevant caption. No other information should be included in the PDF (i.e. do not include authors' names, institutional affiliations, date, etc.) except for the journal name (Cancer Immunology, Immunotherapy), followed by the year of submission in parentheses and by the full name of the first author. Example: Cancer Immunology, Immunotherapy (submitted in 2015) - John Smith et al.
Revisions must not be highlighted in on-line only materials, but should be explained in the point-by-point response to the reviewer comments.
On publication, supplementary files will be named (Electronic) Supplementary Material (1), (2), etc.
Integrity of research and reporting
Ethical standards
Manuscripts submitted for publication must contain a statement to the effect that all human and animal studies have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted.
The editors reserve the right to reject manuscripts that do not comply with the above-mentioned requirements. The author will be held responsible for false statements or failure to fulfill the above-mentioned requirements
Conflict of interest
Authors must indicate whether or not they have a financial relationship with the organization that sponsored the research. This note should be added in a separate section before the reference list.
If no conflict exists, authors should state: The authors declare that they have no conflict of interest.
Does Springer provide English language support?
Manuscripts that are accepted for publication will be checked by our copyeditors for spelling and formal style. This may not be sufficient if English is not your native language and substantial editing would be required. In that case, you may want to have your manuscript edited by a native speaker prior to submission. A clear and concise language will help editors and reviewers concentrate on the scientific content of your paper and thus smooth the peer review process.
The following editing service provides language editing for scientific articles in all areas Springer publishes in.
Use of an editing service is neither a requirement nor a guarantee of acceptance for publication.
Please contact the editing service directly to make arrangements for editing and payment.
For Authors from China
文章在投稿前进行专业的语言润色将对作者的投稿进程有所帮助。作者可自愿选择使用Springer推荐的编辑服务，使用与否并不作为判断文章是否被录用的依据。提高文章的语言质量将有助于审稿人理解文章的内容，通过对学术内容的判断来决定文章的取舍，而不会因为语言问题导致直接退稿。作者需自行联系Springer推荐的编辑服务公司，协商编辑事宜。
理文编辑
For Authors from Japan
ジャーナルに論文を投稿する前に、ネイティブ・スピーカーによる英文校閲を希望されている方には、Edanz社をご紹介しています。サービス内容、料金および申込方法など、日本語による詳しい説明はエダンズグループジャパン株式会社の下記サイトをご覧ください。
エダンズ グループ ジャパン
For Authors from Korea
영어 논문 투고에 앞서 원어민에게 영문 교정을 받고자 하시는 분들께 Edanz 회사를 소개해 드립니다. 서비스 내용, 가격 및
신청 방법 등에 대한 자세한 사항은 저희 Edanz Editing Global 웹사이트를 참조해 주시면 감사하겠습니다.
Edanz Editing Global
After acceptance
Upon acceptance of your article you will receive a link to the special Author Query Application at Springer’s web page where you can sign the Copyright Transfer Statement online and indicate whether you wish to order OpenChoice and offprints.
Once the Author Query Application has been completed, your article will be processed and you will receive the proofs.
Open Choice
In addition to the normal publication process (whereby an article is submitted to the journal and access to that article is granted to customers who have purchased a subscription), Springer now provides an alternative publishing option: Springer Open Choice. A Springer Open Choice article receives all the benefits of a regular subscription-based article, but in addition is made available publicly through Springer’s online platform SpringerLink.
Springer Open Choice
Copyright transfer
Authors will be asked to transfer copyright of the article to the Publisher (or grant the Publisher exclusive publication and dissemination rights). This will ensure the widest possible protection and dissemination of information under copyright laws.
Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under the Creative Commons Attribution License.
Offprints
Offprints can be ordered by the corresponding author.
Color illustrations
Publication of color illustrations is free of charge.
Proof reading
The purpose of the proof is to check for typesetting or conversion errors and the completeness and accuracy of the text, tables and figures. Substantial changes in content, e.g., new results, corrected values, title and authorship, are not allowed without the approval of the Editor.
After online publication, further changes can only be made in the form of an Erratum, which will be hyperlinked to the article.
Online First
The article will be published online after receipt of the corrected proofs. This is the official first publication citable with the DOI. After release of the printed version, the paper can also be cited by issue and page numbers.   
编辑部信息 所在地： 巴尔的摩 国家 美国   
  Editors-in-Chief

Papers from the Americas, China and Japan to:
S. Ostrand-Rosenberg
University of Maryland Baltimore County (UMBC)
Department of Biological Sciences
1000 Hilltop Circle
Baltimore, MD 21250
e-mail: srosenbe@umbc.edu
Papers from all geograhical areas except the Americas, China and Japan to:
G. Pawelec
Center for Medical Research (ZMF)
University of Tübingen Medical School
Waldhörnlestrasse 22
D-72072 Tübingen
Germany
e-mail: CII.pawelec@t-online.de
 
Editorial Board
A. Anichini, Milan, Italy
C. Baxevanis, Athens, Greece
J. Berzofsky, Bethesda, MD
B. Blazar, Minneapolis, MN
C. M. Britten, Mainz, Germany
O. Bruserud, Bergen, Norway
X. Cao, Shanghai, China
W. E. Carson III, Columbus, OH
C. Caruso, Palermo, Italy
F. Cavallo, Turin, Italy
E. Celis, Augusta, GA
A. Choudhury, Brisbane, Australia
M. P. Colombo, Milan, Italy
P. Coulie, Brussels, Belgium
L. Coussens, Portland, OR
A. G. Dalgleish, London, UK
W. Den Otter, Amsterdam, The Netherlands
J. Y. Djeu, Tampa, FL
F. Farzaneh, London, UK
S. Ferrone, Pittsburgh, PA
O. Finn, Pittsburgh, PA
D. Gabrilovich, Philadelphia, PA
F. Garrido, Granada, Spain
M. J. Glennie, Southampton, UK
J. Greenman, Hull, UK
P. Hersey, Sydney, Australia
R. Kiessling, Stockholm, Sweden
E. C. Lattime, New Brunswick, NJ
F. M. Marincola, Doha, Qatar
C. J. M. Melief, Leiden, The Netherlands
E. Naumova, Sofia, Bulgaria
M. Nishimura, Chicago, IL
A. K. Palucka, Dallas, TX
M. Pfreundschuh, Homburg/Saar, Germany
G. Rabinovich, Buenos Aires, Argentina
R. Rees, Nottingham, UK
T. Sayers, Frederick, MD
J. Schlom, Bethesda, MD
R. D. Schreiber, St. Louis, MO